Keytruda has been approved since 2016 as a second-line option after chemotherapy for patients with more advanced HNSCC that ...

Drugmaker AstraZeneca on Wednesday said that its experimental breast cancer treatment improved patient survival without the ...

China’s DeepSeek shocked the world by delivering unexpected innovation at an unbelievable price. But this disruptive trend ...

New York State Common Retirement Fund grew its position in AstraZeneca PLC (NASDAQ:AZN – Free Report) by 7.4% during the 4th ...

Find insight on AstraZeneca, Celltrion and more in the latest Market Talks covering the Health Care sector.

Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing ...

The results showed statistically significant and clinically meaningful improvement in progression-free survival compared with ...

The Australian Renewable Energy Agency (ARENA) will provide A$8 million ($5 million) to technology firm Licella for a study ...

Pharmaceuticals major AstraZeneca said on Wednesday that its experimental treatment, camizestrant, improved survival in ...

The prevalence of type 2 diabetes is rising globally, with a disproportionate impact on individuals in low-income and middle-income countries, where access to care and new therapies is often limited.

The data highlight the possibility of SGLT 1/2 inhibitors having protective effects beyond heart failure and diabetes.